Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Cash & Equivalents (2019 - 2025)

Lyell Immunopharma (LYEL) has disclosed Cash & Equivalents for 7 consecutive years, with $60.2 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 43.01% to $60.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $60.2 million through Dec 2025, down 43.01% year-over-year, with the annual reading at $60.2 million for FY2025, 43.01% down from the prior year.
  • Cash & Equivalents hit $60.2 million in Q4 2025 for Lyell Immunopharma, down from $123.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $564.4 million in Q2 2021 to a low of $60.2 million in Q4 2025.
  • Historically, Cash & Equivalents has averaged $189.9 million across 5 years, with a median of $129.5 million in 2024.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 192.76% in 2021 and later tumbled 70.44% in 2022.
  • Year by year, Cash & Equivalents stood at $293.8 million in 2021, then plummeted by 57.95% to $123.6 million in 2022, then rose by 17.88% to $145.6 million in 2023, then dropped by 27.5% to $105.6 million in 2024, then plummeted by 43.01% to $60.2 million in 2025.
  • Business Quant data shows Cash & Equivalents for LYEL at $60.2 million in Q4 2025, $123.6 million in Q3 2025, and $98.8 million in Q2 2025.